Annette Hay - Dissemin

Language
Login

All papers authored by Annette Hay

This paper is made freely available by the publisher.

2023 Laura K. Hilton

ORCID

ORCID

, Brett Collinge

ORCID

, Kostiantyn Dreval, Susana Ben-Neriah

ORCID

, Christopher K. Rushton, Jasper C. H. Wong

ORCID

, Manuela Cruz, Andrew Roth, Merrill Boyle, Barbara Meissner, Graham W. Slack, Pedro Farinha

ORCID

, Jeffrey W. Craig

ORCID

, Alina S. Gerrie

ORCID

and 16 other authors

Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma

Download from doi.org

This paper was not found in any repository, but could be made available legally by the author.

Julie Stakiw, Shruthi Kodad, Richard LeBlanc

ORCID

, Michael Sebag, Annette E. Hay

ORCID

, Vishal Kukreti, Julie Côté, Fernando Camacho, Molei Fu, Engin Gul

ORCID

, Donna Reece

A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients with Relapsed and Refractory Multiple Myeloma

Upload

This paper is made freely available by the publisher.

2021 Kelvin K. W. Chan, Matthew C. Cheung, Dean A. Regier, Annette Hay

ORCID

, Alexander V. Louie, Winson Y. Cheung, Jean-Eric Tarride, Suji Udayakumar

ORCID

, Nicole Mittmann

The Past, Present, and Future of Economic Evaluations of Precision Medicine at the Committee for Economic Analyses of the Canadian Cancer Trials Group

Download from doi.org

This paper was not found in any repository, but could be made available legally by the author.

Matthew C. Cheung

ORCID

, Kelvin Kw Chan, Shane Golden, Annette Hay

ORCID

, Joseph Pater, Anca Prica, Bingshu E. Chen, Natasha Leighl, Nicole Mittmann

Minimization of resource utilization data collected within cost-effectiveness analyses conducted alongside Canadian Cancer Trials Group phase III trials

Upload

This paper was not found in any repository, but could be made available legally by the author.

Joseph C. Del Paggio

ORCID

, Adam M. Fundytus

ORCID

, Wilma M. Hopman, Joseph L. Pater

ORCID

, Bingshu E. Chen

ORCID

, Michael D. Brundage, Annette E. Hay

ORCID

, Christopher M. Booth

Application of Value Frameworks to the Design of Clinical Trials: The Canadian Cancer Trials Group Experience

Upload

This paper is made freely available by the publisher.

Anca Prica, Annette E. Hay

ORCID

, Michael Crump, Nicole Mittmann, Lois E. Shepherd, Ralph M. Meyer, Kevin I. Imrie, Nancy Risebrough, Marina Djurfeldt, Bingshu E. Chen, Matthew C. Cheung

Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Download from doi.org

This paper is made freely available by the publisher.

2020 Sarit Assouline, Shen Li, Christian Gisselbrecht, Patrick Fogarty, Annette Hay

ORCID

, Eric van den Neste, Lois E. Shepherd, Norbert Schmitz, Tara Baetz, Armand Keating, Sue Robinson, Matthew Seftel, Caterina Stelitano, Marina S. Djurfeldt, Ralph Meyer and 2 other authors

The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL

Download from doi.org

This paper was not found in any repository, but could be made available legally by the author.

Bethany E. Monteith

ORCID

, Chris Venner, Donna E. Reece, Andrea K. Kew, Marc Lalancette, Jocelyn S. Garland, Lois E. Shepherd

ORCID

, Joseph L. Pater, Annette E. Hay

ORCID

Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature

Upload

This paper is made freely available by the publisher.

2017 Michael Crump, Sattva S. Neelapu, Umar Farooq, Eric Van Den Neste, John Kuruvilla, Jason Westin, Brian K. Link

ORCID

, Annette Hay

ORCID

, James R. Cerhan, Liting Zhu, Sami Boussetta, Lei Feng, Matthew J. Maurer, Lynn Navale, Jeff Wiezorek and 2 other authors

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

Download from www.bloodjournal.org

This paper is made freely available by the publisher.

Annette E. Hay

ORCID

, Y. W. Leung, J. L. Pater, M. C. Brown, E. Bell, D. Howell, Z. Kassam, S. Willing, C. Tian, G. Liu

Linkage of clinical trial and administrative data: a survey of cancer patient preferences

Download from doi.org

Distributing this paper is prohibited by the publisher

Tanya Skamene, Michael Crump, Kerry J. Savage, Tony Reiman, John Kuruvilla, David Good, David LeBrun, Ralph M. Meyer, Laurie H. Sehn, Denis Soulières, Julie Stakiw, Nicole Laferriere, Stefano Luminari, Lois E. Shepherd, Marina Djurfeldt and 3 other authors

Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study

Upload

This paper is made freely available by the publisher.

2016 K. Davison, B. E. Chen, V. Kukreti, S. Couban, A. Benger, N. L. Berinstein, L. Kaizer, P. Desjardins, J. Mangel, L. Zhu, M. S. Djurfeldt, A. E. Hay

ORCID

, L. E. Shepherd, M. Crump

Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the Phase III CCTG LY.12 Trial

Download from academic.oup.com

This paper was not found in any repository, but could be made available legally by the author.

Matthew D. Seftel, John Kuruvilla, Tom Kouroukis, Versha Banerji, Graeme Fraser, Michael Crump, Rajat Kumar, Haji I. Chalchal, Muhammad Salim, Rob C. Laister, Susan Crocker, Spencer B. Gibson, Marcia Toguchi, John F. Lyons, Hao Xu and 4 other authors

The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group

Upload

This paper is made freely available by the publisher.

Ming Han, Alli Murugesan, Nizar J. Bahlis, Kevin Song, Darrell White, Christine Chen, Matthew D. Seftel, Kang Howsen-Jan, Donna Reece, Keith Stewart, Yagang Xie, Annette E. Hay

ORCID

, Lois Shepherd, Marina Djurfeldt, Liting Zhu and 3 other authors

A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma

Download from www.bloodjournal.org

Distributing this paper is prohibited by the publisher

Tara Baetz, Bingshu E. Chen

ORCID

, Stephen Couban, C. Tom Kouroukis, Rena Buckstein, John Kuruvilla, Kang Howson-Jan, David Szwajcer, Massimo Federico, Ralph M. Meyer, Marina S. Djurfeldt, Annette E. Hay

ORCID

, Lois Shepherd, Michael Crump

Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12*

Upload

This paper is made freely available by the publisher.

A. E. Hay

ORCID

, C. Rae, G. A. Fraser, R. M. Meyer, L. S. Abbott, S. Bevan, M. L. McBride, G. D. E. Cuvelier, S. McKillop, R. D. Barr

Accrual of adolescents and young adults with cancer to clinical trials

Download from doi.org

This paper is made freely available by the publisher.

P. A. Tang, A. E. Hay

ORCID

, C. J. O’Callaghan, N. Mittmann, C. R. Chambers, J. L. Pater, N. B. Leighl

Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC Clinical Trials Group phase III clinical trials in Canada

Download from dx.doi.org

This paper was not found in any repository, but could be made available legally by the author.

2015 Jose G. Monzon, Annette E. Hay

ORCID

, Gail T. McDonald, Joseph L. Pater, Ralph M. Meyer, Eric Chen, Bingshu E. Chen, Janet E. Dancey

Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome

Upload

Distributing this paper is prohibited by the publisher

Annette E. Hay

ORCID

, Alli Murugesan, Ashley M. DiPasquale, Tom Kouroukis, Irwindeep Sandhu, Vishal Kukreti, Nizar J. Bahlis, Johan Lategan, Donna E. Reece, John F. Lyons, Joana Sederias, Hao Xu, Jean Powers, Lesley K. Seymour, Tony Reiman

A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191

Upload

This paper is made freely available by the publisher.

John Kuruvilla

ORCID

, David A. MacDonald, C. Tom Kouroukis, C. Tom Kouroukis, Matthew Cheung, Harold J. Olney, A. Robert Turner, A. Robert Turner, Peter Anglin, Matthew Seftel, Walid Sabry Ismail, Stefano Luminari, Stephen Couban, Tara Baetz, Ralph M. Meyer and 6 other authors

Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: A subset analysis of NCIC CTG LY12

Download from www.bloodjournal.org

Missing publications? Search for publications with a matching author name.